2023
Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costs
2020
Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases 2020, 73: e1927-e1935. PMID: 32730625, PMCID: PMC8492162, DOI: 10.1093/cid/ciaa1061.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHIV transmissionAge 15High-risk young menAdolescent Medicine Trials NetworkAntiretroviral therapy initiationIncremental cost-effectiveness ratioNew HIV infectionsLife expectancyYoung menCost-effectiveness ratioFrequent HIVCD4 countHIV screeningTherapy initiationHIV infectionClinical outcomesHIV incidenceClinical benefitFrequent screeningART costsHIVAge 30Trials NetworkYMSM
2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2015
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. The Journal Of Infectious Diseases 2015, 213: 1523-1531. PMID: 26681778, PMCID: PMC4837902, DOI: 10.1093/infdis/jiv523.Peer-Reviewed Original ResearchConceptsStandard prepSouth African womenPreexposure prophylaxisHIV infectionHigh riskHuman immunodeficiency virus (HIV) infectionEffective prevention optionsAfrican womenImmunodeficiency virus infectionCost-saving interventionHIV infection riskYoung South African womenLikely clinical benefitInjectable PrEPPrEP formulationsEligible womenClinical benefitPotential ClinicalVirus infectionOutcome measuresPrEP strategiesProgram costsPrevention optionsSurvival rateGreater adherence
2013
Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal Of Medicine 2013, 369: 1715-1725. PMID: 24171517, PMCID: PMC3913536, DOI: 10.1056/nejmsa1214720.Peer-Reviewed Original ResearchConceptsEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapySerodiscordant couplesHIV transmissionHIV Prevention Trials Network 052 studyIncremental cost-effectiveness ratioCost-effectiveness ratioResource-limited settingsHIV infectionClinical benefitImmunodeficiency virusHIV treatmentLonger survivalOpportunistic diseasesEarly initiationFive yearsLifetime outcomesPublic healthSuch personsPatientsPeriodTherapyInfectionDisease
2011
The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, Paltiel AD. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: 26-35. PMID: 21068674, PMCID: PMC3005842, DOI: 10.1097/qai.0b013e3181fb8f24.Peer-Reviewed Original ResearchConceptsVoluntary HIV screeningQuality-adjusted life yearsHIV screeningLife yearsHIV case detectionHIV testing costsTest acceptance rateIncremental cost-effectiveness ratioSubstantial clinical benefitIncidence/prevalenceOne-time screeningDirect medical costsLife expectancyQuality-adjusted life expectancyCost-effectiveness ratioAntiretroviral therapyAnnual incidenceClinical benefitHIV prevalenceClinical impactCase detectionMedical costsCare ratesHIVTest acceptance
2009
Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival loss
2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness